Carisma Therapeutics Inc. received a nasdaq delisting notice notice regarding other.
“October 9, 2025, Carisma Therapeutics Inc. (the “Company”) received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing Rules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025. The Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities and Exchange Commissio”
Listing & Compliance Notices
Carisma Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“January 6, 2025, Carisma Therapeutics Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upo”
Sohanya Cheng was elected as Director at Carisma Therapeutics Inc..
“On October 30, 2024, the Board elected Sohanya Cheng as a director of the Company, effective October 31, 2024.”
Michael Torok resigned as Director at Carisma Therapeutics Inc..
“On October 24, 2024, Michael Torok notified Carisma Therapeutics Inc. (the “Company”) of his decision to resign from the Company’s board of directors (the “Board”), effective October 31, 2024.”
David Scadden was elected as Director at Carisma Therapeutics Inc..
“On June 26, 2024, the board of directors elected Marella Thorell and David Scadden, M.D. as directors of the Company, effective June 30, 2024.”
Marella Thorell was elected as Director at Carisma Therapeutics Inc..
“On June 26, 2024, the board of directors elected Marella Thorell and David Scadden, M.D. as directors of the Company, effective June 30, 2024.”
Björn Odlander resigned as Director at Carisma Therapeutics Inc..
“On June 26, 2024, each of Regina Hodits, Ph.D. and Björn Odlander, M.D., Ph.D. notified Carisma Therapeutics Inc. (the “Company”) of their respective decisions to resign from the Company’s board of directors, effective June 30, 2024.”
Regina Hodits resigned as Director at Carisma Therapeutics Inc..
“On June 26, 2024, each of Regina Hodits, Ph.D. and Björn Odlander, M.D., Ph.D. notified Carisma Therapeutics Inc. (the “Company”) of their respective decisions to resign from the Company’s board of directors, effective June 30, 2024.”
Earnings Releases
Carisma Therapeutics Inc. reported financial results for the quarter ended March 31, 2024.
“On May 9, 2024, Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.”
Earnings Releases
Carisma Therapeutics Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
“On April 1, 2024, Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.